Pneumonia, Bacterial
91
8
11
54
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Published Results
15 trials with published results (16%)
Research Maturity
54 completed trials (59% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
4.4%
4 terminated out of 91 trials
93.1%
+6.6% vs benchmark
15%
14 trials in Phase 3/4
28%
15 of 54 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 54 completed trials
Clinical Trials (91)
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose
MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia
Comparative Study of Adherence to Antibiotic Therapy Among Pediatric Patients: Hospital Emergency Department vs. Primary Care Center
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age
" Study of the Benefit of Nebulized Amikacin in the Treatment of Gram-negative Bacillus Pneumonia Acquired During Mechanical Ventilation in Patients Receiving Extracorporeal Membrane Veno-arterial Oxygenation "
Combination vs. Monotherapy for Stenotrophomonas Maltophilia Infections
A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age
Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years
Impact of BioFire FilmArray Pneumonia Panel vs Routine Diagnostics on Antimicrobial Outcomes (DOOR-MAT)
MASTERMIND-Pneumonia Study (Also Known as Pneumonia Direct Pilot)
Systematic Search for Primary Immunodeficiency in Adults With Infections
Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients
Derivation and Validation of the Risk Evaluation Score for Pneumonia Involving Resistant Entities (RESPIRE)
Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia
Discharge Stewardship in Children's Hospitals
Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Patients With Hospital-acquired Pneumonia
A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants
Urine Pneumococcal Antigen Project
Different Methods of Aerosolized Polymyxin B Inhalation for Treating Carbapenem-Resistant Gram-Negative Bacterial Pneumonia.
Urease Breath Test for Rapid Characterization of Pneumonia